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Objectives This study sought to compare the efﬁcacy of passive stent coating with titanium-nitride-oxide
(TiNO) with drug-eluting stents releasing zotarolimus (ZES) (Endeavor, Medtronic, Minneapolis, Minnesota).
Background Stent coating with TiNO has been shown to reduce restenosis compared with bare-
metal stents in experimental and clinical studies.
Methods In an assessor-blind noninferiority study, 302 patients undergoing percutaneous coronary
intervention were randomized to treatment with TiNO or ZES. The primary endpoint was in-stent
late loss at 6 to 8 months, and analysis was by intention to treat.
Results Both groups were well balanced with respect to baseline clinical and angiographic charac-
teristics. The TiNO group failed to reach the pre-speciﬁed noninferiority margin for the primary end-
point (in-stent late loss: 0.64  0.61 mm vs. 0.47  0.48 mm, difference: 0.16, upper 1-sided 95%
conﬁdence interval [CI]: 0.26; pnoninferiority  0.54), and subsequent superiority testing was in favor
of ZES (psuperiority  0.02). In-segment binary restenosis was lower with ZES (11.1%) than with TiNO
(20.5%; psuperiority  0.04). A stratiﬁed analysis of the primary endpoint found particularly pro-
nounced differences between stents among diabetic versus nondiabetic patients (0.90  0.69 mm
vs. 0.39  0.38 mm; pinteraction  0.04). Clinical outcomes showed a similar rate of death (0.7% vs.
0.7%; p  1.00), myocardial infarction (5.3% vs. 6.7%; p  0.60), and major adverse cardiac events
(21.1% vs. 18.0%, hazard ratio: 1.19, 95% CI: 0.71 to 2.00; p  0.50) at 1 year. There were no differ-
ences in rates of deﬁnite or probable stent thrombosis (0.7% vs. 0%; p  0.51) at 1 year.
Conclusions Compared with TiNO, ZES was superior with regard to late loss and binary restenosis. The
concept of passive stent coating with TiNO remains inferior to drug-eluting stent technology in reducing
restenosis. ([TIDE] Randomized Trial Comparing Titan Stent With Zotarolimus-Eluting Stent:
NCT00492908)
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Early generation drug-eluting stents (DES) have success-
fully addressed the problem of restenosis inherent to bare-
metal stents but have been associated with an increased risk
of very late stent thrombosis (1–5). Efforts to resolve the
problem of very late stent thrombosis include newer generation
DES with drug release from more biocompatible polymers and
passive stent coatings, which mitigate the proinﬂammatory and
thrombotic response to stent-mediated arterial injury in the
absence of drug release (6–9). The newer generation Endeavor
stent (Medtronic, Minneapolis, Minnesota) releases zotaroli-
mus, a sirolimus analog, from the biocompatible phosphoryl-
choline polymer applied to a cobalt chromium alloy, thin-strut
stent surface (10). Although angiographic studies revealed a
somewhat higher late loss with zotarolimus-eluting stents
(ZES) than the Taxus paclitaxel-eluting stent (Boston Scien-
tiﬁc, Natick, Massachusetts), ZES showed similar clinical
efﬁcacy as paclitaxel-eluting stents in the large-scale
ENDEAVOR IV (Randomized, Controlled Trial of the
Medtronic Endeavor Drug-Eluting Coronary Stent System
Versus the Taxus Paclitaxel-Eluting Coronary Stent System in
De Novo Native Coronary Artery Lesions) and ZEST (Com-
parison of the Efﬁcacy and Safety of Zotarolimus-Eluting
Stent With Sirolimus-Eluting and Paclitaxel-Eluting Stent
for Coronary Lesions) trials (7,11,12). During long-term
follow-up, the incidence of very late stent thrombosis was
exceedingly low and signiﬁcantly lower than with paclitaxel-
eluting stents (13).
Passive stent coating with titanium-nitride-oxide (TiNO)
has been shown to diminish platelet adhesion and ﬁbrino-
gen binding in vitro and to reduce neointimal hyperplasia in
the porcine restenosis model (14). Moreover, TiNO was
found to be superior in terms of late loss, restenosis, and
target lesion revascularization (TLR) compared with bare-
metal stents in a randomized clinical trial (9). We therefore
hypothesized that passive stent coating with TiNO would
provide similar efﬁcacy in terms of neointimal hyperplasia
suppression as a DES releasing zotarolimus. The present
study was designed to compare the angiographic outcome
between TiNO-coated stents (Titan2 stent, Hexacath,
Rueil-Malmaison, France) and ZES (Endeavor) in a ran-
domized, assessor-blind, noninferiority trial.
Methods
Patient population. Patients who were at least 18 years of
age with stable or unstable angina pectoris or non–ST-
segment elevation myocardial infarction and signs of myo-
cardial ischemia were eligible if they had at least 1 lesion
with a diameter stenosis of 50% or more that was suitable
for coronary stent implantation in a vessel with a reference
vessel diameter ranging from 2.25 to 4.0 mm. The following
exclusion criteria were applied: patients unable to provide
informed consent; participation in another trial before
reaching the primary endpoint; and patients with known
intolerance to aspirin, clopidogrel, heparin, stainless steel,
titanium, zotarolimus, or contrast material. The study com-
plied with the Declaration of Helsinki and was approved by
the institutional review boards of all participating institu-
tions. Written informed consent was obtained from all
patients. The study was an investigator-initiated study and
there was no industry involvement in the design, conduct,
ﬁnancial support, or analysis of the study.
Study design and procedures. The study was a randomized
assessor-blind, noninferiority trial performed in 3 institu-
tions in Switzerland. Randomization was performed after
diagnostic angiography and before percutaneous coronary
intervention. Sequentially numbered, sealed, opaque,
tamper-proof security envelopes (Envelock Safety Enve-
lopes, Plasto-Sac Ltd., Yavne, Israel) were used, which were
independently monitored by an academic clinical trials unit.
The allocation schedule was based on computer-generated
random numbers, stratiﬁed according to trial center and
catheter laboratory, and blocked, with block sizes of 2, 4,
and 6 varying randomly. Patients were assigned on a 1:1
basis to treatment with a TiNO-
coated stent (Titan 2) or ZES
(Endeavor).
TiNO-coated stents were avail-
able in diameters of 2.25 to 4.0
mm and in lengths of 7 to 28
mm. ZES were available in di-
ameters of 2.25 to 4.0 mm and
in lengths of 8 to 30 mm. Bal-
loon angioplasty and coronary
stent implantation were per-
formed using standard tech-
niques; direct stenting was al-
lowed and performed at the
discretion of the investigator. Full lesion coverage was
attempted by implanting 1 or several stents. Crossover to a
nonstudy stent was allowed to complete the procedure
successfully, in the event that the assigned study stent could
not be implanted. In case more than 1 lesion was treated in
a given patient in the same session or in a staged procedure
during the index hospitalization, the remaining lesions were
still treated with the originally assigned study stent.
All patients were treated with at least 100 mg of acetyl-
salicylic acid and 300 to 600 mg of clopidogrel bisulfate
before or at the time of the procedure. During percutaneous
coronary intervention, unfractionated heparin in a dose of at
least 5,000 IU or 70 to 100 IU/kg was administered to
maintain an activated clotting time 250 s. The use of
glycoprotein IIb/IIIa antagonists was left to the discretion of
the operator. Creatine kinase (CK), CK-myocardial band, and
troponin were assessed 6 h after the procedure and either at
18 h after the procedure or at hospital discharge, whichever
came ﬁrst. A 12-lead electrocardiogram was obtained before
and within 24 h after the procedure or for any suspicion of
Abbreviations
and Acronyms
CI  conﬁdence interval
CK  creatine kinase
DES  drug-eluting stent(s)
IQR  interquartile range
TiNO  titanium-nitride-oxide
TLR  target lesion
revascularization
ZES  zotarolimus-eluting
stent(s)
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acute ischemia. In case of elevated cardiac enzymes after the
procedure, CK, CK-myocardial band, and troponin measure-
ments were continued every 8 h until the peak of the biomark-
ers had been conclusively deﬁned. All patients were discharged
on acetylsalicylic acid 100 mg daily indeﬁnitely and clopidogrel
bisulfate 75 mg daily for an intended duration of 3 months.
Quantitative coronary angiography. Coronary angiograms
were digitally recorded at baseline, immediately after the
procedure, and at follow-up and were assessed at the
angiographic core laboratory of Bern University Hospital.
Readers of angiograms were blinded to the assigned study
stent. The projections that best showed the stenosis were
used for all analyses. Measurements were performed on the
cineangiograms after maximum vasodilation with nitroglyc-
erin and the contrast-ﬁlled, nontapered catheter tip was
used for calibration (6-F guiding catheter). Digital angio-
grams were analyzed with the help of an automated edge-
detection system (QAngio XA, Version 7/1/14.Zero, Medis
Medical Imaging Systems, Leiden, the Netherlands). Quantita-
tive measurements included the diameter of the reference
vessel, the minimal luminal diameter, percent diameter
stenosis (difference between reference vessel diameter and
minimal luminal diameter/reference diameter  100), and
late lumen loss (difference between minimal lumen diameter
after the procedure and minimal lumen diameter at follow-
up). Binary restenosis was deﬁned as stenosis of 50% or
greater of the minimal lumen diameter in the target lesion
Figure 1. Patient and Lesion Flow
Patient and lesion ﬂow according to CONSORT (Consolidated Standards for Reporting of Trials) (16). TiNO  titanium-nitride-oxide.
Table 1. Baseline Clinical Characteristics
TiNO-Coated Stent
(n  152)
ZES
(n  150)
Age, yrs 65.9  9.0 63.4 10.5
Male 124 (81.6) 118 (78.7)
Cardiac risk factors
Diabetes mellitus 30 (19.7) 28 (18.7)
Insulin-requiring diabetes 7 (4.6) 10 (6.7)
Hypertension 105 (69.1) 113 (75.3)
Hypercholesterolemia 115 (75.7) 122 (81.3)
Current smoking 53 (34.9) 43 (28.7)
Family history of CAD 45 (29.6) 47 (31.3)
Past medical history
Myocardial infarction 42 (27.6) 32 (21.3)
PCI 39 (25.7) 38 (25.3)
With drug-eluting stent 18 (11.8) 22 (14.7)
Previous CABG 12 (7.9) 4 (2.7)
Clinical characteristics
Stable coronary artery disease 88 (57.9) 71 (47.3)
Unstable angina 14 (9.2) 16 (10.7)
Non–ST-segment elevation myocardial infarction 50 (32.9) 63 (42.0)
Left ventricular ejection fraction 56.5 10.6 57.8 10.1
Multivessel disease 36 (23.7) 38 (25.3)
Small vessel disease, RVD 2.75 mm 81 (53.3) 74 (49.3)
Long lesions, 20 mm 33 (21.7) 42 (28.0)
Average number of lesions per patient 1.5 0.7 1.5 0.7
Values are mean SD or n (%).
CABG coronary artery bypass grafting; CAD coronary artery disease; PCI percutaneous
coronary intervention; RVD reference vessel diameter; TiNO titanium-nitride-oxide;
ZES zotarolimus-eluting stent(s).

ht
tp
://
do
c.
re
ro
.c
h
at angiographic follow-up. All angiographic measurements
of the target lesion were obtained in the stented area, within
the margins 5 mm proximal and distal to each stent edge
(in-stent), and over the entire segment (in-segment).
Study endpoints and deﬁnitions. Adverse events were as-
sessed at 1, 6, and 12 months. All patients were asked to
return for an angiographic follow-up study at 6 to 8 months.
An independent clinical event committee whose members
Table 2. Procedural Results
TiNO-Coated Stent
(n  229)
ZES
(n  222)
Difference
Estimate (95% CI) p Value
Pre-procedural results
Lesion length, mm 13.1 8.1 14.2 8.9 1.2 (2.8 to 0.5) 0.17
RVD, mm 2.88 0.47 2.90 0.53 0.03 (0.13 to 0.07) 0.53
Minimal lumen diameter, mm 0.85 0.49 0.82 0.53 0.03 (0.07 to 0.12) 0.60
Stenosis, % lumen diameter 71.0 15.3 72.2 16.4 1.2 (4.2 to 1.9) 0.45
Procedural results
Number of study stents per lesion 1.28 0.55 1.17 0.45 0.11 (0.01 to 0.21) 0.03
Maximal stent diameter per lesion, mm 3.02 0.46 3.01 0.50 0.00 (0.09 to 0.09) 1.00
Total stent length per lesion, mm 19.3 11.1 19.6 10.0 0.3 (2.4 to 1.8) 0.76
Direct stenting 76 (33.2) 66 (29.7) 3.5 (5.4 to 12.3) 0.44
Implantation of study stent 221 (96.5) 219 (98.7) 2.1 (5.1 to 0.8) 0.16
Device success 213 (93.0) 210 (94.6) 1.6 (6.8 to 3.6) 0.55
Lesion success 219 (95.6) 213 (96.0) 0.3 (4.1 to 3.5) 0.87
Minimal lumen diameter, mm
In-stent 2.60 0.45 2.64 0.49 0.05 (0.13 to 0.04) 0.31
In-segment 2.31 0.54 2.34 0.55 0.03 (0.14 to 0.07) 0.54
Diameter stenosis, %
In-stent 10.35 6.07 9.80 5.11 0.54 (0.54 to 1.58) 0.33
In-segment 18.65 8.25 17.94 8.20 0.70 (0.84 to 2.24) 0.37
Acute gain, mm
In-stent 1.75 0.51 1.83 0.56 0.07 (0.17 to 0.03) 0.17
In-segment 1.46 0.57 1.52 0.57 0.06 (0.17 to 0.04) 0.26
Values are mean SD or n (%).
CI conﬁdence interval; other abbreviations as in Table 1.
Table 3. Angiographic Follow-Up Results (Primary Outcome)
TiNO-Coated Stent
(n  186) ZES (n  172)
Difference
Estimate (95% CI) p Value
Reference vessel diameter, mm 2.81 (0.45) 2.85 (0.54) 0.05 (0.16 to 0.06) 0.36
Minimal lumen diameter, mm
In-stent 1.93 0.75 2.16 0.69 0.23 (0.39 to0.06) 0.01
In-segment 1.80 0.71 2.00 0.67 0.19 (0.35 to0.03) 0.02
Diameter stenosis, %
In-stent 31.86 22.71 24.62 18.23 6.57 (1.79 to 11.35) 0.01
In-segment 35.49 21.21 29.07 16.72 6.03 (1.64 to 10.42) 0.01
Late loss, mm
In-stent* 0.64 0.61 0.47 0.48 0.16 (0.03 to 0.28) 0.02
In-segment 0.48 0.55 0.36 0.44 0.12 (0.00 to 0.23) 0.04
Binary restenosis
In-stent 36 (19.4) 18 (10.5) 8.9 (0.40 to 18.16) 0.06
In-segment 38 (20.5) 19 (11.1) 9.43 (0.23 to 18.63) 0.04
Values aren (%) ormean SD. The95%CI andpvalues are 2-sided, fromsuperiority testing. *Noninferiority testing for difference inmeansof in-stent
late luminal loss: Difference 0.16, upper 1-sided 95% CI 0.26, noninferiority margin 0.15, 1-sided p value 0.54.
Abbreviations as in Tables 1 and 2.
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were unaware of the patient’s treatment assignment adjudi-
cated all clinical endpoints. The primary endpoint of the
study was in-stent late loss at 6 to 8 months after stent
implantation as assessed by quantitative coronary angiogra-
phy. Secondary angiographic endpoints included in-
segment late loss as well as in-stent and in-segment binary
restenosis, minimal luminal diameter, and percent diameter
stenosis. Secondary clinical endpoints included: death; car-
diac death; myocardial infarction; clinically and nonclini-
cally indicated TLR; and the composite of cardiac death,
myocardial infarction, or clinically indicated target lesion
revascularization at 30 days, 6 months, and 1 year.
The deﬁnition of cardiac death included any death due to
immediate cardiac cause (e.g., myocardial infarction, low-
output failure, fatal arrhythmia); procedure-related deaths,
including those related to concomitant treatment; unwit-
nessed death; and death of unknown cause. Myocardial
infarction was deﬁned using the electrocardiographic crite-
ria of the Minnesota Code Manual, or as an elevation of CK
levels to more than 2 times the upper limit of normal with
positive levels of CK-myocardial band or troponin. TLR
was deﬁned as any repeat PCI within the stent or within the
5-mm borders adjacent to the stent, or bypass surgery of the
target vessel. Revascularization of the target lesion and
vessel was regarded as clinically indicated if the stenosis on
any target lesion or vessel was at least 50% of the diameter
of the vessel on the basis of quantitative coronary angiog-
raphy in the presence of recurrent angina or objective signs
of ischemia, or if the stenosis was at least 70% of the
diameter of the vessel even in the absence of ischemic signs
and symptoms. Stent thrombosis was deﬁned according to
the Academic Research Consortium deﬁnition as deﬁnite,
probable, or possible (15).
Statistical analysis. This was a noninferiority trial, which
was powered for noninferiority on the primary endpoint
in-stent late lumen loss at 6 to 8 months. Based on
angiographic outcomes reported for the ENDEAVOR II
(Randomized Controlled Trial to Evaluate the Safety and
Efﬁcacy of the Medtronic AVE ABT-578 Eluting Driver
Coronary Stent in De Novo Native Coronary Artery Le-
sions) trial (11) and the TINOX (Randomized Comparison
of a Titanium-Nitride-Oxide–Coated Stent With a Stain-
less Steel Stent for Coronary Revascularization) study (9),
we postulated the following in-stent late lumen loss values:
ZES 0.61  0.46 mm; TiNO 0.55  0.63 mm. Assuming
a noninferiority margin of 0.15 mm as the acceptable
difference between TiNO and ZES to claim TiNO nonin-
feriority to ZES, an average number of 1.5 lesions per
patient, a design factor of 1.1 to take into account the
correlation of lesions within patients, and a 1-sided type-1
error of 0.05, we estimated that 234 patients (117 patients in
each group) will yield 80% power to detect noninferiority.
To account for patients not undergoing repeat angiography
6 to 8 months after the procedure (typically 20% to 25% of
the overall patient population), we pre-speciﬁed a total
enrollment of 300 patients.
Baseline clinical characteristics, pre-procedural, proce-
dural, and follow-up angiographic results (including the
primary endpoint in-stent late lumen loss) are reported as
mean  SD for continuous variables and absolute numbers
and percentages for categorical variables. For the angio-
Figure 2. Cumulative Distribution of In-Stent Late Loss and
Cumulative Frequency Distribution of In-Stent Percent Diameter Stenosis
(A) Cumulative distribution of in-stent late loss shown separately for the 2
stent types. The cumulative distribution curve of in-stent late loss is shifted
to the right for titanium-nitride-oxide (TiNO) relative to zotarolimus-eluting
stent (ZES), indicating that neointimal hyperplasia was more effectively
reduced with ZES. (B) Cumulative frequency distribution curves of percent
in-stent diameter stenosis shown separately for the stent types. There was
no difference in measurements before and immediately after the procedure
between the 2 stent types. At follow-up angiography, the cumulative distri-
bution curve of percent in-stent diameter stenosis is shifted to the right for
TiNO compared with ZES, indicating that in-stent diameter stenosis was
more effectively reduced with ZES. TiNO  continuous lines; ZES 
dotted lines.
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graphic results, the differences (including 95% conﬁdence
interval [CI] and p value) between the 2 treatment groups
were calculated using multilevel mixed-effects linear or
logistic models that allowed for correlation of multiple
lesions within patients. Stratiﬁed analyses were performed
for the primary outcome according to the presence or
absence of diabetes, lesions located in the left anterior
descending artery, multivessel intervention, small vessel
disease, long lesions, and age (65 years vs. 65 years). To
determine whether there was an interaction between treat-
ment group and these characteristics, we used a likelihood-
ratio test. We used the Mantel-Cox model and the corre-
sponding log-rank test for between-group comparison of
clinical outcomes occurring up to 1 month, up to 6 months,
and up to 1 year. The duration of clopidogrel prescription
between both treatment groups was compared using the
Wilcoxon rank sum test. All patients who underwent
randomization were included in the analysis in the groups to
which they were originally allocated to (intention-to-treat
principle). Analyses of angiographic outcomes were re-
stricted to lesions from patients who attended follow-up
angiography at 6 to 8 months (2 months). In a sensitivity
analysis, only the ﬁrst lesion of each patient was analyzed on
angiographic outcomes. Analyses were performed by a
statistician (A.L.) who was blinded to the allocated treat-
ment. No adjustments were made for multiple comparisons
in secondary analyses; all p values and 95% CI are 2-sided.
All analyses were done in Stata (version 11.0, StataCorp,
College Station, Texas).
Results
Figure 1 summarizes the trial proﬁle and patient ﬂow (16).
Between June 2007 and September 2008, 302 patients with
451 lesions were randomly assigned to treatment with either
TiNO (152 patients, 229 lesions) or ZES (150 patients, 222
lesions). One hundred forty-six patients allocated to TiNO
(96.1%) and 148 patients allocated to ZES (98.7%) received
at least 1 allocated study stent. No patient allocated to
TiNO and 2 patients allocated to ZES (1.3%) were lost to
follow-up or withdrew consent before reaching 12 months.
Baseline clinical characteristics are shown in Table 1 and are
similar in both groups. Procedural characteristics including
number of treated lesions, the distribution of lesion location,
and rate of direct stenting, as well as lesion and stent
length were similar among patients treated with TiNO
and ZES (Table 2). More stents per lesion were im-
planted in the TiNO group than in the ZES group (1.3
vs. 1.2; p  0.03). Implantation of the allocated study stent
occurred with similar frequency in both groups (96.5% vs.
98.7%; p  0.16). Device and lesion success were compa-
rable for the 2 devices as were the angiographic lesion
measurements before and after stent implantation (Table
2). Median length of clopidogrel prescription was 4.0
TiNO coated stent
[n=186 lesions]
Zotarolimus eluting stent
[n=172 lesions]
Difference
Number of 
patients
Mean (SD)
Number of 
patients
Mean (SD)
Estimate (95% CI) P-value for 
interaction*
Overall 122 0.64 (0.61) 117 0.47 (0.48) 0.16 (0.03 to 0.28)
-0.2 0 0.2 0.4 0.6 0.8
    Difference (95% CI)
Diabetes mellitus
Yes 20 0.90 (0.69) 17 0.39 (0.38) 0.50 (0.21 to 0.79) 0.04
No 102 0.59 (0.58) 100 0.49 (0.50) 0.10 (-0.04 to 0.23)
Left anterior descending
Yes 53 0.54 (0.51) 47 0.43 (0.46) 0.11 (-0.05 to 0.28) 0.47
No 69 0.71 (0.66) 70 0.50 (0.49) 0.19 (0.02 to 0.36)
Multivessel intervention
Yes 29 0.52 (0.51) 32 0.38 (0.41) 0.14 (-0.05 to 0.32) 0.93
No 93 0.71 (0.64) 85 0.55 (0.52) 0.15 (-0.01 to 0.32)
Small vessel disease
Yes 65 0.67 (0.62) 62 0.44 (0.49) 0.22 (0.05 to 0.40) 0.23
No 57 0.60 (0.58) 55 0.53 (0.45) 0.07 (-0.11 to 0.25)
Long lesions
Yes 25 0.71 (0.64) 33 0.54 (0.58) 0.18 (-0.11 to 0.48) 0.92
No 97 0.62 (0.60) 84 0.44 (0.42) 0.17 (0.03 to 0.31)
Age > 65 years
Yes 62 0.71 (0.66) 51 0.44 (0.51) 0.25 (0.04 to 0.45) 0.16
No 60 0.56 (0.54) 66 0.50 (0.45) 0.07 (-0.09 to 0.22)
Figure 3. Stratiﬁed Analyses for Primary Outcome
Subgroup analysis of the primary endpoint, in-stent late loss, among patients randomized to treatment with TiNO or ZES. *p values for interaction between
treatment group and corresponding stratiﬁcation factor. CI  conﬁdence interval; other abbreviations as in Figures 1 and 2.
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Table 4. Clinical Outcomes
TiNO-Coated Stent
(n  152)
ZES
(n  150) Hazard Ratio (95% CI) p Value
Events at 30 days
Death 0 1 (0.7) 0.33 (0.01–8.01) 0.50*
Cardiac death 0 0 — —
Myocardial infarction 5 (3.3) 5 (3.3) 0.99 (0.28–3.48) 0.98
Q-wave 1 (0.7) 1 (0.7) 0.99 (0.06–15.90) 1.00*
Non–Q-wave 4 (2.6) 4 (2.7) 0.98 (0.24–4.00) 0.98
Clinically indicated TLR 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Percutaneous 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Surgical 0 0 — —
Any TLR 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Percutaneous 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Surgical 0 0 — —
Clinically indicated TVR 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Percutaneous 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Surgical 0 0 — —
Any TVR 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Percutaneous 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Surgical 0 0 — —
Any repeat revascularization 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Percutaneous 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Surgical 0 0 — —
Death or MI 5 (3.3) 6 (4.0) 0.82 (0.25–2.74) 0.75
Cardiac death or MI 5 (3.3) 5 (3.3) 0.99 (0.28–3.48) 0.98
Cardiac death, MI, or clinically indicated TLR 5 (3.3) 5 (3.3) 0.99 (0.28–3.48) 0.98
MACE (cardiac death, MI, or clinically indicated TVR) 5 (3.3) 5 (3.3) 0.99 (0.28–3.48) 0.98
Events at 6 months
Death 1 (0.7) 1 (0.7) 0.98 (0.06–15.80) 1.00*
Cardiac death 0 0 — —
Myocardial infarction 6 (4.0) 6 (4.0) 0.99 (0.31–3.11) 0.98
Q-wave 1 (0.7) 1 (0.7) 0.99 (0.06–15.90) 1.00*
Non–Q-wave 5 (3.3) 5 (3.3) 0.98 (0.28–3.44) 0.98
Clinically indicated TLR 6 (4.0) 1 (0.7) 5.96 (0.72–49.50) 0.06
Percutaneous 5 (3.3) 1 (0.7) 4.96 (0.58–42.51) 0.10
Surgical 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Any TLR 6 (4.0) 1 (0.7) 5.96 (0.72–49.50) 0.06
Percutaneous 5 (3.3) 1 (0.7) 4.96 (0.58–42.51) 0.10
Surgical 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Clinically indicated TVR 7 (4.6) 2 (1.3) 3.51 (0.73–16.94) 0.10
Percutaneous 6 (4.0) 2 (1.3) 3.00 (0.60–14.90) 0.16
Surgical 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Any TVR 7 (4.6) 2 (1.3) 3.51 (0.73–16.94) 0.10
Percutaneous 6 (4.0) 2 (1.3) 3.00 (0.60–14.90) 0.16
Surgical 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Any repeat revascularization 9 (5.9) 3 (2.0) 3.00 (0.81–11.08) 0.08
Percutaneous 8 (5.3) 3 (2.0) 2.66 (0.70–10.02) 0.13
Surgical 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Death or MI 7 (4.6) 7 (4.7) 0.98 (0.34–2.85) 0.98
Cardiac death or MI 6 (4.0) 6 (4.0) 0.99 (0.31–3.11) 0.98
Cardiac death, MI, or clinically indicated TLR 10 (6.6) 7 (4.7) 1.41 (0.53–3.75) 0.49
MACE (cardiac death, MI, or clinically indicated TVR)* 11 (7.2) 8 (5.3) 1.36 (0.54–3.41) 0.51
Continued on next page
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months in patients treated with TiNO (interquartile
range [IQR]: 3.0 to 10.6 months) and 7.0 months in
patients treated with ZES (IQR: 3.1 to 12.0 months; p
value for difference  0.06).
Angiographic outcomes. Angiographic follow-up was com-
pleted according to protocol in 239 of 302 patients (79.1%)
with 358 of 451 lesions (79.4%) at a median follow-up of
7.9 months (IQR: 7.4 to 8.9 months) (Table 3). A total of
122 patients (80.3%) allocated to TiNO and 117 patients
(78.0%) allocated to ZES underwent follow-up angiography
(p  0.63). Patients with angiographic follow-up were
younger (63.9 vs. 67.6; p  0.008) and were less frequently
diabetic (15.5% vs. 33.3%; p  0.001) and hypertensive
(69.5% vs. 82.5%, p  0.04). Among patients undergoing
angiographic follow-up, clinical baseline characteristics were
similar between TiNO and ZES, with the exception of age
(65.5 vs. 62.3 years; p  0.01).
The TiNO group failed to reach the pre-speciﬁed non-
inferiority margin (difference: 0.16, upper 1-sided 95% CI:
0.26; pnoninferiority  0.54) (Table 3). In-stent late loss was
signiﬁcantly lower with ZES than TiNO (0.47  0.48 mm
vs. 0.64 0.61 mm; psuperiority 0.02). In-segment late loss
was also lower with ZES than TiNO (0.36  0.44 mm vs.
0.48  0.55 mm; psuperiority  0.04). Consistent results in
favor of ZES were observed for measurements of in-stent
and in-segment minimal lumen diameter and percent di-
ameter stenosis. As a result, a signiﬁcant reduction of
in-segment binary restenosis was observed with ZES versus
TiNO groups (11.1% vs. 20.5%; psuperiority  0.04). The
cumulative distribution of in-stent late lumen loss for the 2
stent groups is shown in Figure 2A. The cumulative
frequencies of in-stent percent diameter stenosis for the 2
stent groups before and after the procedure, and at
follow-up angiography are shown in Figure 2B. Figure 3
shows the results of stratiﬁed analyses of the primary
endpoint. Results were consistent among patients with or
without lesions located in the left anterior descending
artery, multivessel intervention, and long lesions. Con-
versely, differences between TiNO and ZES appeared
more pronounced among diabetic compared with nondi-
abetic patients, patients with or without small vessel
disease, and patients aged below or above 65 years.
However, a p value for interaction reached conventional
Table 4. Continued
TiNO-Coated Stent
(n  152)
ZES
(n  150) Hazard Ratio (95% CI) p Value
Events at 1 yr
Death 1 (0.7) 1 (0.7) 0.98 (0.06–15.80) 1.00*
Cardiac death 0 0 — —
Myocardial infarction 8 (5.3) 10 (6.7) 0.78 (0.30–1.99) 0.60
Q-wave 1 (0.7) 1 (0.7) 0.99 (0.06–15.90) 1.00*
Non–Q-wave 7 (4.6) 9 (6.0) 0.76 (0.28–2.04) 0.58
Clinically indicated TLR 22 (14.5) 13 (8.7) 1.74 (0.87–3.46) 0.11
Percutaneous 21 (13.8) 11 (7.3) 1.95 (0.94–4.07) 0.07
Surgical 2 (1.3) 2 (1.3) 0.98 (0.14–6.93) 1.00*
Any TLR 26 (17.1) 17 (11.3) 1.57 (0.85–2.90) 0.15
Percutaneous 24 (15.8) 15 (10.0) 1.64 (0.86–3.13) 0.13
Surgical 3 (2.0) 2 (1.3) 1.46 (0.24–8.77) 0.66
Clinically indicated TVR 27 (17.8) 20 (13.3) 1.39 (0.78–2.50) 0.27
Percutaneous 26 (17.1) 17 (11.3) 1.57 (0.85–2.91) 0.15
Surgical 2 (1.3) 3 (2.0) 0.65 (0.11–3.89) 0.63
Any TVR 31 (20.4) 23 (15.3) 1.39 (0.81–2.39) 0.24
Percutaneous 29 (19.1) 20 (13.3) 1.50 (0.84–2.65) 0.17
Surgical 3 (2.0) 3 (2.0) 0.97 (0.20–4.83) 0.97
Any repeat revascularization 41 (20.4) 30 (15.3) 1.42 (0.89–2.29) 0.14
Percutaneous 39 (25.7) 28 (18.7) 1.45 (0.89–2.36) 0.14
Surgical 3 (2.0) 3 (2.0) 0.97 (0.20–4.83) 0.97
Death or MI 9 (5.9) 11 (7.3) 0.80 (0.33–1.94) 0.62
Cardiac death or MI 8 (5.3) 10 (6.7) 0.78 (0.30–1.99) 0.60
Cardiac death, MI, or clinically indicated TLR 27 (17.8) 21 (14.0) 1.29 (0.73–2.29) 0.39
MACE (cardiac death, MI, or clinically indicated TVR) 32 (21.1) 27 (18.0) 1.19 (0.71–2.00) 0.50
Values are presented as n (%). Hazard ratios are fromMantel-Coxmodel. p values are 2-sided from superiority testing using a log-rank test. Note that
a continuity correction of 0.5 was used in case of 0 events in 1 group. *Fisher exact test.
MACEmajor adverse cardiac event(s);MImyocardial infarction; TLR target lesion revascularization; TVR target vessel revascularization;
other abbreviations as in Tables 1 and 2.
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levels of signiﬁcance only in the case of diabetic mellitus
(p  0.04).
Clinical outcomes. At 30 days, adverse events were rare, and
there were no differences with respect to ischemic and
revascularization endpoints among patients randomized to
TiNO or ZES (Table 4). At 6 months, revascularization
procedures by any deﬁnition (clinically indicated TLR, any
TLR, clinically indicated target vessel revascularization, any
target vessel revascularization, any repeat revascularization
procedure) tended to be more common among patients
randomized to TiNO than to ZES (Table 4). This trend
remained sustained up to 1 year, but there were no differ-
ences with respect to death, cardiac death, or myocardial
infarction. Similarly, major adverse cardiac events—the
composite of cardiac death, myocardial infarction. and
clinically indicated target vessel revascularization—showed
no signiﬁcant differences between TiNO and ZES up to 1
year (Fig. 4A). Cumulative incidence curves of clinically
indicated TLR began to diverge as early as 4 months after
the procedure in favor of ZES (Fig. 4B). Rates of deﬁnite,
probable, and possible stent thrombosis during the early and
late time periods were low and comparable for both stent
types (Table 5).
Discussion
In this randomized, assessor-blind, noninferiority trial,
compared with ZES, passive stent coating with TiNO failed
to reach noninferiority for the primary endpoint, in-stent
late lumen loss. The zotarolimus-eluting DES was found
superior to TiNO in all angiographic measurements includ-
ing in-segment binary restenosis at 6 to 8 months. Corre-
spondingly, there was a trend toward fewer repeat revascu-
larization procedures.
Restenosis following percutaneous coronary interventions
is the result of a vasculo-proliferative cascade in response to
stent-mediated arterial injury (17). Several concepts have
been put forward to attenuate neointimal hyperplasia in
response to iatrogenic arterial injury associated with stent
implantation. Changes in stent strut conﬁguration, thick-
ness, and geometry, as well as primary stent implantation
aim to reduce arterial injury and thereby the extent of
neointimal hyperplasia (18–20). Passive stent coatings at-
tempt to mitigate the proinﬂammatory and thrombotic
response to stent-mediated arterial injury and, thereby, the
impact on the vasculo-proliferative response (14). Finally,
active stent coatings with release of antiproliferative drugs or
radioactivity directly inhibit smooth muscle cell prolifera-
tion and migration, as well as extracellular matrix formation
to minimize neointimal hyperplasia (21,22).
The latter concept has proved successful in the form of
early generation DES with important reductions in the need
for repeat revascularization procedures compared with bare-
metal stents (1,2). However, the problem of very late stent
thrombosis emerged as a distinct entity particularly among
more complex patient and lesion subsets (5). To overcome
this limitation, newer generation DES have been developed
with thinner struts, more biocompatible polymers, and
lower drug concentrations, such as the ZES used in the
present study. Passive stent coating with TiNO is an
alternative concept. Titanium has improved biocompatibil-
ity compared with stainless steel as well as cobalt chromium
alloys, owing to higher corrosion resistance and less tissue
reactivity. Moreover, TiNO-coated stents resulted in less
neointimal hyperplasia in a porcine restenosis model and
were superior in terms of restenosis and repeat revascular-
ization in a small randomized clinical study (9,14).
Figure 4. Composite of Cardiac Death, Myocardial Infarction, or
Clinically Indicated Target Vessel Revascularization
(A) Kaplan-Meier curves show the cumulative incidence of the composite
endpoint of cardiac death, myocardial infarction, and clinically indicated
target vessel revascularization up to 12-month follow-up for TiNO and ZES.
(B) Kaplan-Meier curves show the cumulative incidence of just clinically
indicated target lesion revascularizations up to 12-month follow-up for
TiNO and ZES. TiNO  continuous lines; ZES  dotted lines. Abbrevia-
tions as in Figures 1 and 2.
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However, the results of the present study indicate that
passive stent coating with TiNO remains inferior to current
DES technology in reducing late loss and binary restenosis.
Compared with previously published data on angio-
graphic outcomes, late loss was lower with ZES in the
present study than that observed in the ENDEAVOR
trials (ENDEAVOR I [First-in-human study of the Endeavor
ABT-578-eluting phosphorylcholine-encapsulated stents system
in de novo native coronary artery lesions] (10): 0.61 0.44 mm;
ENDEAVOR II (11): 0.61 0.46 mm; ENDEAVOR II CA
[Safety of direct stenting with the Endeavor stent: results of the
Endeavor II continued access registry] [23]: 0.58  0.58 mm;
ENDEAVOR III [Randomized Controlled Trial of the
Medtronic Endeavor Drug-Eluting Coronary Stent System
Versus the Cypher Sirolimus-Eluting Coronary Stent Sys-
tem in De Novo Native Coronary Artery Lesions] [24]:
0.60  0.48 mm; ENDEAVOR IV [7]: 0.67  0.49 mm).
However, CIs overlap widely, indicating that the present
results are compatible with previous reports. When restrict-
ing the analysis to patients with only 1 lesion, mean late loss
was somewhat higher and amounted to 0.56  0.54 mm and
0.67 0.57 mm in ZES and TiNO, respectively. We noted
heterogeneity of results for the primary endpoint according
to diabetic status. Thus, the difference in late loss between
TiNO (0.90  0.69 mm) and ZES (0.39  0.38 mm; p 
0.001) was particularly pronounced among diabetic patients,
and a test for interaction reached conventional levels of
signiﬁcance. Diabetic patients are at increased risk of
restenosis, and DES have been found particularly effective
in this high-risk cohort (25). The differences between
passive stent coating using TiNO and DES were more
accentuated in diabetic patients in the present study, and
therefore, DES remain ﬁrst-line therapy in this patient
population. Differences between the 2 stent platforms were
also more pronounced among patients with small vessels
and the elderly (age 65 years) favoring ZES. However, a
test for interaction failed to reach signiﬁcance and the
ﬁndings, therefore, may reﬂect the play of chance.
Study limitations. The present study was designed for an
angiographic endpoint and, therefore, is too small to
qualify as a clinical endpoint study. Although late loss
was signiﬁcantly lower with ZES than TiNO, clinical
outcomes through 1 year showed similar results in terms
of major adverse cardiac events for both stent platforms,
and differences in revascularization procedures were likely
driven by protocol-mandated angiographic follow-up.
Another limitation is the lack of longer-term clinical and
angiographic follow-up beyond 1 year. It cannot be
excluded that the 2 stent platforms have a differential
impact on long-term vessel remodeling. Thus, longitudi-
nal angiographic follow-up series of patients treated with
bare-metal stents suggest late improvements in lumen
diameter beyond the early period of neointimal prolifer-
ation, whereas a late catch-up phenomenon has been
observed with early generation DES (26). Notwithstand-
ing, ZES represents a newer generation DES, and
long-term clinical follow-up indicates low rates of repeat
revascularization up to 3 years (13). Finally, the overall
number of patients studied with TiNO is rather small,
and therefore, the available evidence is limited as com-
pared to that for established DES platforms.
Table 5. Stent Thrombosis
TiNO-Coated Stent
(n  152)
ZES
(n  150) Hazard Ratio (95% CI) p Value
Deﬁnite stent thrombosis
0 to 30 days 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
30 days to 12 months 0 0 — —
0 days to 12 months 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Probable stent thrombosis
0 to 30 days 0 0 — —
30 days to 12 months 0 0 — —
0 days to 12 months 0 0 — —
Possible stent thrombosis
0 to 30 days 0 0 — —
30 days to 12 months 0 0 — —
0 days to 12 months 0 0 — —
Deﬁnite or probable stent thrombosis
0 to 30 days 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
30 days to 12 months 0 0 — —
0 days to 12 months 1 (0.7) 0 2.96 (0.12–72.11) 0.51*
Data are presented as n (%). Hazard ratios are from Mantel-Cox model, and p values are 2-sided from superiority testing using a log-rank test. Note
that a continuity correction of 0.5 was used in case of 0 events in 1 group. *Fisher exact test.
Abbreviations as in Tables 1 and 2.
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Conclusions
Compared with TiNO, ZES is superior with regard to late
loss and binary restenosis. The concept of passive stent
coating with TiNO remains inferior to current DES tech-
nology in reducing restenosis.
Reprint requests and correspondence: Dr. Stephan Windecker,
Department of Cardiology, Bern University Hospital, 3010 Bern,
Switzerland. E-mail: stephan.windecker@insel.ch.
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